Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii
- Authors:
- Guangming Ren
- Min Zhou
- Ning Ding
- Ning Zhou
- Qingling Li
View Affiliations
Affiliations: Department of Pneumology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221000, P.R. China
- Published online on: July 11, 2016 https://doi.org/10.3892/etm.2016.3513
-
Pages:
1715-1718
-
Copyright: © Ren
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the present study was to examine the clinical distribution and drug resistance of Acinetobacter baumannii infection, and provide evidence of clinical medication as well as the prophylaxis for the treatment of drug resistance bacteria. In total, 306 Acinetobacter baumanniis selected from routine culture were collected between January 2012 and December 2013, to analyze the distributions among clinical specimens and wards and their drug resistance state. Of the 306 Acinetobacter baumanniis, the main distribution of specimens was sputum, accounting for 77.78%. The distribution of administrative office was dominated by intensive care unit with a proportion of 40.0% in 2012, which rapidly increased to 60.9% in 2013, followed by neurosurgery, respiration medicine and orthopedics with proportions of 23, 12 and 9.0% in 2012 and 9.71, 8.74 and 3.88% in 2013, respectively. The Acinetobacter baumannii's drug resistance rate of Tazobactam and Piperacillin was increased from 68.0% in 2012 to 71.36% in 2013. At the same time, the drug resistance rate of imipenem was enhanced from 66.0% in 2012 to 72.81% in 2013. By 2013, the drug resistance rates of penbritin, ceftizoxime, cefotetan and macrodantin reached ≤100%. In conclusion, Acinetobacter baumannii mainly causes respiratory tract infection with severe drug resistance. The drug resistance of Acinetobacter baumannii was mainly manifested as multidrug resistance or even pan‑drug resistance with an obvious increasing trend of tolerance. Thus, it is necessary to prevent and treat nosocomial infection, to minimize usage of antibiotics and to standardize medical operating, to reduce the increase in persistence.
View References
1
|
Giamarellou H, Antoniadou A and
Kanellakopoulou K: Acinetobacter baumannii: A universal
threat to public health? Int J Antimicrob Agents. 32:106–119. 2008.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Mishra SK, Rijal BP and Pokhrel BM:
Emerging threat of multidrug resistant bugs-Acinetobacter
calcoaceticus baumannii complex and methicillin resistant
Staphylococcus aureus. BMC Res Notes. 6:982013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Krcmery V and Kalavsky E:
Multidrug-resistant Acinetobacter baumannii. Emerg Infect
Dis. 13:943–944. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Zhu X, Zhang M, Wang S, et al: The
clinical distribution and drug-resistant analysis of
baumanii's infection in the hospital. Lab Med. 27:788–790.
2012.(In Chinese).
|
5
|
Gootz TD and Marra A: Acinetobacter
baumannii: An emerging multidrug-resistant threat. Expert Rev
Anti Infect Ther. 6:309–325. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Du J and Li W: Distribution and resistance
analysis of 148 Acinetobacter baumannii clinical isolates.
Lab Med Clinic. 10:155–156. 2013.
|
7
|
Hsueh PR, Ko WC, Wu JJ, Lu JJ, Wang FD, Wu
HY, Wu TL and Teng LJ: Consensus statement on the adherence to
Clinical and Laboratory Standards Institute (CLSI) Antimicrobial
Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update)
for Enterobacteriaceae in clinical microbiology laboratories
in Taiwan. J Microbiol Immunol Infect. 43:452–455. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Mochizuki T, Okamoto N, Yagishita T,
Takuhiro K, Mashiko K, Ogawa F, Tosaka N, Kurokawa A and Yamamoto
Y: Analysis of antimicrobial drug resistance of Staphylococcus
aureus strains by WHONET 5: Microbiology laboratory database
software. J Nippon Med Sch. 71:345–351. 2004. View Article : Google Scholar : PubMed/NCBI
|
9
|
Luo P, Dai W and Zhang L: Clinical
distribution and drug resistance analysis of 1582 Acinetobacter
baumannii. Chongqing Med. 40:224–228. 2011.(In Chinese).
|
10
|
Zhang Y, Jia W and Zhao Z: The clinical
distribution and drug-resistant analysis of baumaniis. Chin
J Nosocomiol. 21:364–366. 2011.
|
11
|
Feng D, Dong F and Xu X: The clinical
distribution and drug-resistant analysis of the baumanii in
PICU. J Xinxiang Med Coll. 25:591–593. 2008.(In Chinese).
|
12
|
Xu G and Long X: The diagnoses of
preventive antibacterials among 570 perioperative patients. J Pract
Clin Med. 12:83–84. 2008.
|
13
|
Peleg AY, Seifert H and Paterson DL:
Acinetobacter baumannii: Emergence of a successful pathogen.
Clin Microbiol Rev. 21:538–582. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Gould IM: The epidemidogy of antibiotic
resistance. Int J Antimicrob Agents (Suppl 1). 32:S2–S9. 2008.
View Article : Google Scholar
|
15
|
Zhu M, Sun X and Jiang R: The research of
multi-drug resistant baumanii's resistance mechanism to 7
kinds of antibacterial agents. Chin J Nosocomiology. 20:2184–2188.
2010.
|
16
|
Mendes RE, Bell JM, Turnidge JD,
Castanheira M and Jones RN: Emergence and widespread dissemination
of OXA-23, −24/40 and −58 carbapenemases among Acinetobacter
spp. in Asia-Pacific nations: Report from the SENTRY Surveillance
Program. J Antimicrob Chemother. 63:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
17
|
Lai Y, Wu J and Yang J: The monitor of
clinical distribution and drug resistantances of baumanii.
China Trop Med. 12:342–344. 2013.(In Chinese).
|